Lyell Immunopharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell LYEL and other ETFs, options, and stocks.

About LYEL

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. 

CEO
Lynn Seely
CEOLynn Seely
Employees
300
Employees300
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2018
Founded2018
Employees
300
Employees300

LYEL Key Statistics

Market cap
781.92M
Market cap781.92M
Price-Earnings ratio
-1.50
Price-Earnings ratio-1.50
Dividend yield
Dividend yield
Average volume
69.24K
Average volume69.24K
High today
$35.16
High today$35.16
Low today
$32.75
Low today$32.75
Open price
$33.80
Open price$33.80
Volume
64.90K
Volume64.90K
52 Week high
$35.16
52 Week high$35.16
52 Week low
$7.65
52 Week low$7.65

Stock Snapshot

The current Lyell Immunopharma(LYEL) stock price is $34.00, with a market capitalization of 781.92M. The stock trades at a price-to-earnings (P/E) ratio of -1.50.

During the trading session on 2025-12-13, Lyell Immunopharma(LYEL) shares reached a daily high of $35.16 and a low of $32.75. At a current price of $34.00, the stock is +3.8% higher than the low and still -3.3% under the high.

Trading volume for Lyell Immunopharma(LYEL) stock has reached 64.9K, versus its average volume of 69.24K.

The stock's 52-week range extends from a low of $7.65 to a high of $35.16.

The stock's 52-week range extends from a low of $7.65 to a high of $35.16.

LYEL News

TipRanks 5d
Lyell Immunopharma Presents Promising CAR T-Cell Data

TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRank...

TipRanks 6d
Lyell Immunopharma announces new data from trial of rondecabtagene autoleucel

Lyell Immunopharma (LYEL) announced new clinical and translational data from the ongoing clinical trial of rondecabtagene autoleucel in patients with large B-ce...

People also own

Based on the portfolios of people who own LYEL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.